SCHEMBL2861894

SCHEMBL2861894

CC(C)(C)OC(=O)N1CCC(n2cnc3cc(C(F)(F)F)ccc32)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
USP2 O75604 3/20 0.56
LMNA P02545 3/20 0.56
GAA P10253 2/20 0.56
HTT P42858 2/20 0.56
POLB P06746 1/20 0.56
MAPK10 P53779 1/20 0.56
HCAR1 Q9BXC0 1/20 0.54
PKM P14618 2/20 0.48
ALDH1A1 P00352 5/20 0.47
HPGD P15428 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
STS P08842 1/20 0.46
GPR119 Q8TDV5 5/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
NR3C1 P04150 1/20 0.45
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12459052 0.85 HCAR1 (0.56) USP2GAAHCAR1ALDH1A1HPGD
SCHEMBL6246964 0.83 HCAR1 (0.59) USP2GAAHCAR1PKMALDH1A1
SCHEMBL5258987 0.83 STS (0.47) USP2HCAR1PKMSTSGPR119
SCHEMBL5450692 0.82 HCAR1 (0.53) USP2GAAHCAR1ALDH1A1HPGD
SCHEMBL2854961 0.81 USP2 (0.69) SMN1; SMN2USP2GAAHTTPKM
SCHEMBL1864820 0.81 HCAR1 (0.52) USP2LMNAGAAHCAR1ALDH1A1
SCHEMBL3093280 0.81 HCAR1 (0.56) GAAHCAR1ALDH1A1HPGDMEN1
SCHEMBL15205388 0.80 HCAR1 (0.57) USP2GAAHCAR1ALDH1A1HPGD
SCHEMBL13135673 0.79 USP2 (0.60) SMN1; SMN2USP2LMNAGAAHTT
SCHEMBL3596413 0.78 HCAR1 (0.56) USP2HCAR1GPR119CTSDCTSE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
CN-100341862-C Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORP (JP) 2007-10-10 CN disclosed
CN-1606549-A Thiazolidine derivative and medical application thereof MITSUBISHI PHARMA CORP (JP) 2005-04-13 CN disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 SMN1; SMN2 3494/4885USP2 3903/4885LMNA 4632/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 SMN1; SMN2 2677/4885USP2 3799/4885LMNA 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.